CBL-514 injection shows promise in reducing visceral fat in early human trials

CBL-514 visceral fat apoptosis obesity treatment clinical trials

Researchers are testing an experimental injection, CBL-514, designed to target and reduce dangerous visceral and liver fat. Unlike traditional weight-loss medications that reduce the volume of existing fat cells, CBL-514 works by inducing apoptosis, a biological process where fat cells are triggered to self-destruct while leaving surrounding tissue unharmed.

Early human trials have shown promising results. Participants receiving the treatment—administered via injections into the lower abdomen every three weeks for up to 12 weeks—saw an average reduction in visceral fat volume of approximately 12% four weeks after their final dose. In separate phase 2 trials, 69.6% of participants receiving the drug achieved a reduction of at least 150 ml in subcutaneous fat over an eight-week period, whereas the placebo group saw no such reduction.

Reducing visceral fat is a significant medical goal, as this deep abdominal fat is metabolically active and strongly linked to insulin resistance, type 2 diabetes, and cardiovascular issues such as heart failure. Researchers suggest that by reducing the total number of fat cells, the body may be less capable of reaccumulating fat, potentially helping to prevent weight regain after treatment ends.

Entities

ARD · Aleksei Isachenko · American Heart Association · Bitkom · Bundesamt für Verbraucherschutz und Lebensmittelsicherheit · CBL-514 · Caliway Biopharmaceuticals · Denmark · Deutsche Gesellschaft für Ernährung · EU Commission · Edeka · European Association for the Study of Diabetes

Claims

What the coverage asserts, and how many sources carry each claim.

[● 3 SOURCES] Leeks, celery, and carrots form the foundation of the vegetable broth recipe.
[● 3 SOURCES] Mushrooms can be added to provide an earthy, umami note to the broth.
[● 3 SOURCES] The broth can be kept fresh in screw-top jars in the refrigerator for approximately one week.
[● 3 SOURCES] Broth can be frozen in ice cube trays or freezer bags for later use.
[● 5 SOURCES] Early human trials of the CBL-514 injection show a reduction in visceral fat. www.it-boltwise.de · www.leinetal24.de · www.hna.de · www.kreiszeitung.de · www.foxnews.com
[● 5 SOURCES] CBL-514 reduced visceral fat volume by an average of 12.01% four weeks after the final treatment. www.it-boltwise.de · www.leinetal24.de · www.hna.de · www.kreiszeitung.de · www.foxnews.com
[○ 1 SOURCE] In phase 2 trials, 69.6% of participants receiving CBL-514 saw a reduction of at least 150 ml in subcutaneous fat over 8 weeks, compared to 0% in the placebo group. alahalygate.com
[● 5 SOURCES] Participants in the study received injections into the lower abdomen every three weeks for up to 12 weeks. www.it-boltwise.de · www.leinetal24.de · www.hna.de · www.kreiszeitung.de · www.foxnews.com
[● 6 SOURCES] CBL-514 works by inducing apoptosis, causing fat cells to self-destruct while leaving surrounding cells unharmed. alahalygate.com · www.it-boltwise.de · www.leinetal24.de · www.hna.de · www.kreiszeitung.de · +1 more
[● 2 SOURCES] The CBL-514 injection was developed through research by the University of Alabama at Birmingham and Caliway Biopharmaceuticals. alahalygate.com · www.foxnews.com